Livzon Pharmaceutical Group Inc
SZSE:000513

Watchlist Manager
Livzon Pharmaceutical Group Inc Logo
Livzon Pharmaceutical Group Inc
SZSE:000513
Watchlist
Price: 37.82 CNY 0.45%
Market Cap: 34.9B CNY
Have any thoughts about
Livzon Pharmaceutical Group Inc?
Write Note

Net Margin
Livzon Pharmaceutical Group Inc

17.1%
Current
15%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.1%
=
Net Income
2B
/
Revenue
11.9B

Net Margin Across Competitors

Country CN
Market Cap 34.8B CNY
Net Margin
17%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Livzon Pharmaceutical Group Inc
Glance View

Market Cap
35B CNY
Industry
Pharmaceuticals

Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.

Intrinsic Value
47.84 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.1%
=
Net Income
2B
/
Revenue
11.9B
What is the Net Margin of Livzon Pharmaceutical Group Inc?

Based on Livzon Pharmaceutical Group Inc's most recent financial statements, the company has Net Margin of 17.1%.